Even though Bristol-Myers Squibb Company's ( NYSE:BMY ) recent earnings release was robust, the market didn't seem ...

DelveInsight’s report on the Moderate to Severe Plaque Psoriasis pipeline highlights a dynamic and evolving landscape, with ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split: ...

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of ...

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...